Last reviewed · How we verify
Standard COVID-19 care
Standard COVID-19 care encompasses supportive and therapeutic interventions including oxygen therapy, antivirals, corticosteroids, and anticoagulation to manage viral infection and prevent severe complications.
Standard COVID-19 care encompasses supportive and therapeutic interventions including oxygen therapy, antivirals, corticosteroids, and anticoagulation to manage viral infection and prevent severe complications. Used for COVID-19 (mild to severe).
At a glance
| Generic name | Standard COVID-19 care |
|---|---|
| Sponsor | Liaquat University of Medical & Health Sciences |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Standard COVID-19 care is a multimodal treatment approach rather than a single drug, typically including oxygen supplementation for hypoxemia, antiviral agents (such as remdesivir) to inhibit viral replication, corticosteroids (such as dexamethasone) to reduce excessive inflammation, and anticoagulation to prevent thrombotic complications. The approach is tailored to disease severity and patient factors.
Approved indications
- COVID-19 (mild to severe)
Common side effects
- Hyperglycemia (corticosteroid-related)
- Thrombocytopenia (anticoagulation-related)
- Secondary infections
- Gastrointestinal disturbance
Key clinical trials
- Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 (PHASE2)
- LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (EARLY_PHASE1)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Nasal Swab Objective and Statistical Evaluation (NOSE Study)
- Building Family Caregiver Skills Using a Simulation-Based Intervention for Care of Cancer Patients (NA)
- COVID-19 Rapid Test-to-Treat With African American Churches (Faithful Response II) (PHASE2)
- Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19) (NA)
- Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard COVID-19 care CI brief — competitive landscape report
- Standard COVID-19 care updates RSS · CI watch RSS
- Liaquat University of Medical & Health Sciences portfolio CI